Human osteosarcoma expresses specific ephrin profiles: implications for tumorigenicity and prognosis.
about
Novel strategy for selection of monoclonal antibodies against highly conserved antigens: phage library panning against ephrin-B2 displayed on yeastGene expression signatures differentiate uterine endometrial stromal sarcoma from leiomyosarcomaEphrinB1 interacts with CNK1 and promotes cell migration through c-Jun N-terminal kinase (JNK) activationPhosphorylation of ephrin-B1 regulates dissemination of gastric scirrhous carcinomaProteolysis of EphA2 Converts It from a Tumor Suppressor to an OncoproteinBone cell interactions through Eph/ephrin: bone modeling, remodeling and associated diseases.Multiple receptor tyrosine kinases promote the in vitro phenotype of metastatic human osteosarcoma cell linesEffects of overexpression of ephrin-B2 on tumour growth in human colorectal cancerThe anti-tumour agent, cisplatin, and its clinically ineffective isomer, transplatin, produce unique gene expression profiles in human cellsSurface proteomic analysis of osteosarcoma identifies EPHA2 as receptor for targeted drug delivery.Diagnostic and prognostic sarcoma signatures.Membrane-mediated regulation of vascular identity.Ephrin expression and function in cancer.Bone microenvironment signals in osteosarcoma development.EphrinA5 suppresses colon cancer development by negatively regulating epidermal growth factor receptor stability.Ephrin-B1 reverse signaling controls a posttranscriptional feedback mechanism via miR-124.EphrinA1 repulsive response is regulated by an EphA2 tyrosine phosphatase.EphrinA5 acts as a tumor suppressor in glioma by negative regulation of epidermal growth factor receptor.EphA2 Targeted Doxorubicin-Nanoliposomes for Osteosarcoma Treatment.EphrinB1 promotes cancer cell migration and invasion through the interaction with RhoGDI1.Chronic hypoxia-induced slug promotes invasive behavior of prostate cancer cells by activating expression of ephrin-B1The osteoprogenitor-specific loss of ephrinB1 results in an osteoporotic phenotype affecting the balance between bone formation and resorption
P2860
Q28479031-24088928-8FF7-4245-B726-129962C25338Q33732473-505B1F13-D12F-48A9-8234-ADEE7D876CFEQ34073875-C3C92D1A-3FFE-41BC-91D1-B74A0574643DQ35928209-36AF1857-082C-459B-BEDA-F26F44F6F975Q36380708-1E9FD70B-D92C-4FD5-A445-2FA3D62CDC79Q36402724-1F529AA1-83B5-44A8-BD19-337ED790F02AQ36438319-A3689B6B-2291-4E28-ACB9-1921CBC9B850Q36694994-7889F754-6477-496D-8A2E-ACC656EB951BQ37055940-CE59B766-900C-4269-B83D-16946D663E8CQ37235596-64AB2509-11AF-4E3A-A546-E8D38B9A41FAQ37335373-76A085D9-30B8-42A7-8FC7-08AD26D46761Q37643632-BEFEA83B-9863-4361-8815-2E67CE0C53B2Q37658786-FD6922A4-D2FF-4F8D-B79F-478EADA9372EQ38454980-AFC9E60D-95AA-419F-ADC8-45CE4E3DAF5AQ39445033-20C32D9E-DA31-4FA5-9EDF-CF8BABC51DF4Q40338388-88197D51-761A-47DC-8935-6CF67296CA8CQ40392006-8EC4EE0D-8B88-4C1E-A6EE-AB247C8742F0Q46095419-44874D8A-96C0-41CD-A698-FAA821E638DFQ47375034-41A3DD93-A65F-42E3-8495-59ED3ADA3EFEQ47616516-7753F6E2-3E08-4899-A885-C568C764003BQ58692417-6E6C1AF9-8D5E-4309-A4FE-B04F131A2A98Q58708207-571092F1-CDA5-4F28-A500-BE170E68742F
P2860
Human osteosarcoma expresses specific ephrin profiles: implications for tumorigenicity and prognosis.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Human osteosarcoma expresses s ...... tumorigenicity and prognosis.
@en
Human osteosarcoma expresses s ...... tumorigenicity and prognosis.
@nl
type
label
Human osteosarcoma expresses s ...... tumorigenicity and prognosis.
@en
Human osteosarcoma expresses s ...... tumorigenicity and prognosis.
@nl
prefLabel
Human osteosarcoma expresses s ...... tumorigenicity and prognosis.
@en
Human osteosarcoma expresses s ...... tumorigenicity and prognosis.
@nl
P2093
P2860
P356
P1433
P1476
Human osteosarcoma expresses s ...... r tumorigenicity and prognosis
@en
P2093
Antiopi Varelias
Christopher D Carter
Mark Clayer
Prudence A Cowled
P2860
P304
P356
10.1002/CNCR.10749
P407
P577
2002-08-01T00:00:00Z